At a glance
- WuXi Biologics will take over Bayer's drug product plant in Leverkusen, Germany.
- The plant will serve as a back-up site for Kovaltry™ production.
- The transaction is expected to conclude in the coming months.
- Financial details were not disclosed.
Acquisition Agreement
WuXi Biologics and Bayer have announced an acquisition agreement where WuXi Biologics Germany GmbH will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany. The agreement includes the purchase of associated equipment and a long-term lease contract for the building.
Manufacturing Agreement
The plant will be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry™, an antihemophilic factor (recombinant). A manufacturing agreement is to be negotiated, and the transaction is expected to be concluded in the coming months, subject to customary closing conditions.
Financial Details
Financial details of the transaction were not disclosed.
